Hesham ElGhazaly

Hesham ElGhazaly

Clinical Oncologist

Breast Oncology, Gynecologic oncology

Ain Shams University

Location Egypt, Cairo

Linkedin

Prof. Hesham ElGhazaly is a Professor of Clinical Oncology at Ain Shams University in Cairo, Egypt, with over 27 years of academic and clinical experience specializing in breast cancer, gynecologic oncology, and cancer control. He currently serves as President of the Egyptian Cancer Society, Chairman of the National Committee for the Presidential Initiative for Women’s Health, Head of the Medical and Scientific Research Institute (MASRI) at Ain Shams University, and Founder and CEO of Alfa Cure Oncology Center. His contributions to cancer research and policy have been recognized internationally, including his election as a Member of the IARC Scientific Committee (WHO) in May 2024 and his appointment to the Board of Directors of the ABC Global Alliance in January 2025.

Current Positions

  • Professor of Clinical Oncology, Ain Shams University, Cairo, Egypt (2014–present)
  • President, Egyptian Cancer Society (December 2024–present)
  • Chairman, National Committee for the Presidential Initiative for Women’s Health, Ministry of Health and Population, Egypt (May 2023–present)
  • Head, Medical and Scientific Research Institute (MASRI), Ain Shams University (2018–present)
  • IARC Scientific Committee Member, International Agency for Research on Cancer / WHO (May 2024–present)
  • Founder and President, Breast Gynecological & Immuno-Oncology International Cancer Society (BGICS) (2004–present)
  • Founder and CEO, Alfa Cure Oncology Center, Cairo, Egypt (2004–present)
  • Board of Directors Member, ABC Global Alliance, representing BGICS for Low- and Middle-Income Countries (January 2025–present)

Education

  • MBBS, Faculty of Medicine, Ain Shams University, 1993
  • Master of Science (MS) in Clinical Oncology, Faculty of Medicine, Ain Shams University, 1998
  • Doctor of Medicine (MD) in Clinical Oncology, Faculty of Medicine, Ain Shams University, 2003

Professional Experience

  • Assistant Lecturer, Clinical Oncology Department, Ain Shams University, 1999–2003
  • Lecturer, Clinical Oncology Department, Ain Shams University, 2003–2008
  • Assistant Professor, Clinical Oncology Department, Ain Shams University, 2008–2014
  • Professor, Clinical Oncology Department, Ain Shams University, 2014–present
  • Member, Supreme Committee for Cancer Control, Egypt, 2017–2022
  • Member, Supreme Committee for the President’s Women’s Health Initiative, Egypt, 2019–2022

Research Activity

  • MASRI (Medical and Scientific Research Institute): Heads this innovative research hub at Ain Shams University, encompassing a Cancer Biobank, Genome Center, clinical and preclinical research centers, and a bioinformatics network; the institute has produced over 150 international publications
  • Presidential Initiative for Women’s Health: Leads the national committee overseeing breast cancer screening, early detection, and updated treatment guidelines across Ministry of Health and university-affiliated hospitals, aligned with Egypt’s Vision 2030 and the UN Sustainable Development Goals
  • BGICC Consensus Guidelines: Chairs and leads international expert consensus panels on triple-negative breast cancer, neoadjuvant therapy, and breast cancer awareness and early detection in low- and middle-income countries, published in leading journals including Cancer, Cancers, and International Journal of Cancer
  • TRIPOLI Study: Contributing investigator in the TRIple-Negative Breast Cancer PrOspective Registry in Middle East and Africa (TRIPOLI), addressing a critical gap in outcomes data for TNBC in the MENA region
  • Hepatocellular Carcinoma: Co-author of the Egyptian Society of Liver Cancer Recommendation Guidelines for HCC Management (Journal of Hepatocellular Carcinoma, 2023)
  • COVID-19 Research: Led and contributed to multiple studies on SARS-CoV-2 genomics, treatment trials, and biomarker discovery during the pandemic
    Active contributor to global cancer burden research, including the GBD Study 2019 (The Lancet, 2022)

Memberships / Honors / Awards

  • Member, IARC Scientific Committee, World Health Organization (2024–present)
  • President, Egyptian Cancer Society (2024–present)
  • Board of Directors, ABC Global Alliance — representing BGICS for Low/Middle-Income Countries (2025–present)
  • Founder and President, BGICS (Breast Gynecological & Immuno-Oncology International Cancer Society) (2004–present)
  • Member, American Society of Clinical Oncology (ASCO)
  • Member, European Society for Medical Oncology (ESMO)

Areas of Specialization

  • Breast oncology and gynecologic oncology
  • Neoadjuvant and systemic therapy for breast cancer
  • Cancer screening and early detection
  • Cancer control and prevention policy
  • Hepatocellular carcinoma management
  • Immuno-oncology and targeted therapy
  • Clinical research and consensus guideline development
  • Cancer awareness and education in low- and middle-income countries

Publications

Prof. ElGhazaly has authored and co-authored more than 100 publications, including peer-reviewed journal articles, international consensus guidelines, book chapters, conference abstracts, and preprints.

Select Recent Publications:

Shaker FH, Sanad EF, Elghazaly H, Hsia SM, Hamdy NM. “piR-823 tale as emerging cancer-hallmark molecular marker in different cancer types: a step toward ncRNA-precision.” Naunyn-Schmiedeberg’s Archives of Pharmacology 398(1):47–68, 2025.

Eldmnawy AT, Tolba MF, Elghazaly H, Wahdan SA. “Trimetazidine protects against doxorubicin-induced chemobrain in rats: insights into energy imbalance and neuroinflammation.” European Journal of Pharmacology, 2025.

Shaat H, Sharafeldin M, Mostafa A, Ismail EH, Hassan MK, Alkordi MH, Elghazaly H, et al. “Microfluidic-based fluorescence enhancement of silica-embedded carbon dots for direct detection and quantification of unamplified HCV RNA in clinical samples.” Analytica Chimica Acta 1333:343396, 2025.

Horgan D, Reduzzi C, Belina I, Lal JA, Pestana R, Bounedjar A, Elghazaly H, et al. “The adoption and integration of artificial intelligence in diagnostics across Europe.” AI in Precision Oncology 2(6):212–222, 2025.

Horgan D, Maravic Z, Mastris K, Mohamad Abu Rasheed H, Reduzzi C, Elghazaly H, et al. “Global trials, local relevance: a scientific and regulatory framework for regional enrollment in cancer drug development.” JCO Global Oncology 12:e2500285, 2026.

Shaker FH, Sanad EF, Ibrahim NM, Elghazaly H, Hsia SM, Hamdy NM. “P-element-induced wimpy testis (PIWI)-interacting RNA-823/PIWIL1/DNMT3B/CDH1 as potential axis to drive EMT, stemness, and tumor aggressiveness in ovarian cancer tissue samples.” International Journal of Molecular Sciences 27(2):823, 2026.

Cibula D, Mburu A, Planchamp F, Zapardiel I, Atallah D, Al-Rubaish S, Elghazaly H, et al. “European Society of Gynaecological Oncology (ESGO) resource-stratified guidelines for the management of patients with cervical cancer.” International Journal of Gynecological Cancer, 2025.

Elghazaly H, Azim HA, Rugo HS, Cameron D, Swain SM, Curigliano G, et al. “Tailoring neoadjuvant systemic therapy in breast cancer: ‘The advent of a personalized approach’ — The BGICC consensus and recommendations.” Cancer 130(19):3251–3271, 2024.

Kassem L, Pöllinger B, Velkovski-Rouyer M, Kandil A, El Zawahry H, Elghazaly H, et al. “Stage-based survival analysis in the TRIple-Negative Breast Cancer PrOspective Registry in Middle East Africa (TRIPOLI) study.” Clinical Cancer Research 31(12_Supplement), 2025.

Shash E, Amin HM, Hussein N, Shaker S, Wafi O, Salah H, Elghazaly H, et al. “2304P Public-private-NGO partnership boosts early breast cancer detection in Egypt: lessons for scaling across LMICs.” Annals of Oncology 36:S1267, 2025.

Amin HM, Shash E, Hussein N, Kassem L, Abdelaziz AH, Abdelalim MA, Elghazaly H, et al. “2315P Governmental pharma-industry partnership transforms Egypt’s breast cancer patient journey: data from the National Breast Cancer Program (2019–2024).” Annals of Oncology 36:S1271–S1272, 2025.

Shaker MK, Omar A, Elghazaly H, Aboualfa G. “Systemic therapy for HCC.” In: Approach to Hepatocellular Carcinoma (HCC) Management in Low/Middle-Income Countries, 2025.

Ibrahim M, Abdeen M, Elwekel H, Elghazaly H, Abbas S. “Impact of cetuximab addition to FOLFIRI as first-line therapy for metastatic colorectal cancer on patient quality of life.” Aswan University Medical Journal, 2025.

Ibrahim M, Abdeen M, Elwekel H, Elghazaly H, Abbas S. “Evaluation of the impact of cetuximab plus FOLFIRI on progression-free survival in patients with newly diagnosed metastatic colorectal cancer.” Aswan University Medical Journal, 2025.

Atherton J, Gopalakrishnan SG, Wahba Y, Kirollos RH, Shash E, Amin HM, Elghazaly H, et al. “Key performance indicators (KPIs) of screening via clinical breast examination (CBE): a pooled analysis of 9.3 million screened women.” ESMO Open 10, 2025.

Yacoub ETT, Mohammed M, Abdelaziz AH, Shash E, ElGhazawy H, et al. “1558P Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population.” Annals of Oncology 35:S946, 2024.

Haggagy AR, Elghazaly HA, Awad NS. “Investigation of immunomodulatory role of honey on cisplatin injected rats.” Aswan Science and Technology Bulletin 4(1):41–59, 2024.

 

All information is sourced from publicly available materials.